A PHASE 3 OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF INTRAVENOUS ATB200 CO-ADMINISTERED WITH ORAL AT2221 IN ADULT SUBJECTS WITH LATE-ONSET POMPE DISEASE
Clinical Trial Grant
Administered By
Pediatrics, Medical Genetics
Awarded By
Amicus Therapeutics Corporation
Start Date
April 13, 2020
End Date
November 30, 2024
Administered By
Pediatrics, Medical Genetics
Awarded By
Amicus Therapeutics Corporation
Start Date
April 13, 2020
End Date
November 30, 2024